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Abstract
Background: Human breast tissue undergoes phases of proliferation, differentiation and regression regulated by
changes of the levels of circulating sex hormones during the menstrual cycle or aging. Ovarian hormones also likely play
a key role in the etiology and biology of breast cancer. Reports concerning the proliferative effects of steroid hormones
on the normal epithelium of human breast have been conflicting. Some studies have shown that steroid hormones may
predispose breast epithelial cells to malignant changes by stimulating their proliferation, which is known to be regulated
tightly by stromal cells.
The aim of this study was to investigate the effects of 17β-estradiol and medroxyprogesterone acetate on proliferation,
apoptosis, expression of differentiation markers and steroid hormone receptors in breast epithelium using an in vitro
model of freshly isolated human breast tissue, in which a proper interaction of breast epithelium and stroma has been
maintained.
Methods: Human breast tissues were obtained from women undergoing surgery for breast tumours. Peritumoral tissues
were excised and explants were cultured for 3 weeks in medium supplemented with E2 or MPA or with E2+MPA.
Endpoints included histopathological, histomorphometric and immunohistochemical assessment of the breast explants.
Results: Culture of breast explants for 14 or 21 days with steroid hormones increased proliferative activity and the
thickness of acinar and ductal epithelium. E2-treatment led to hyperplastic epithelial morphology, MPA to hypersecretory
single-layered epithelium and E2+MPA to multilayered but organised epithelium.
The proliferative response to E2 in comparison to control (p < 0.001) was more pronounced than to MPA (p < 0.05) or
E2+MPA (p < 0.05) at 7 and 14 days for Ki-67 and PCNA. E2 treatment also decreased the proportion of apoptotic cells
after 7 (p < 0.01) and 14 (p < 0.01) days. In addition, the relative number of ERα, ERβ and PR positive epithelial cells was
decreased by all hormonal treatments.
Conclusion: Organ culture system provides a model for studying the direct effects of steroid hormones and their
analogues on postmenopausal human breast tissue.
Addition of E2 or MPA or E2+MPA to breast explants caused characteristic changes in morphology, stimulated epithelial 
proliferation, lowered apoptosis ratio and decreased the relative number of epithelial cells expressing ERα, ERβ and PR.
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Breast cancer is the most common malignancy among
women especially in developed countries [1]. Its inci-
dence strongly correlates with age and rises steadily to
reach a peak in the postmenopausal age. Simultaneously,
post menopause is associated with low levels of ovarian
steroids leading to unwanted climacteric symptoms and
illnesses, such as vasomotor symptoms, mood and sexual
dysfunction, osteoporosis and bone fractures.
Estrogen-alone or in combination with progestins has
been widely used for hormone replacement therapy (HT)
for prevention and treatment of these conditions [2].
Despite the benefits of HT, some studies have shown that
HT may increase the risk of breast cancer. One of the
mechanisms suggested for carcinogenesis is that endog-
enous estrogens and progesterone, as well as their syn-
thetic and/or exogenously administered derivates
influence cell proliferation in breast glandular tissue [3,4].
Stimulation of proliferation predisposes epithelial cells to
occurrence of somatic mutations and eventually to malig-
nant changes [5], especially during long-term HT [6,7].
However, recent results from WHI suggested that treat-
ment with estrogen-alone does not increase breast cancer
incidence in postmenopausal women with prior hysterec-
tomy [8].
Conflicting results have been obtained from in vitro and in
vivo studies concerning the role of estrogen and especially
of progestins in breast epithelial cell proliferation and in
breast carcinogenesis [9].
In vivo the proliferative activity of breast epithelial cells is
highest during luteal phase of menstrual cycle coinciding
with high serum estrogen and progesterone levels [10-14].
On the other hand, in vitro studies on breast cell lines have
shown that estrogen increases cell proliferation, but addi-
tion of progesterone has an antiproliferative effect [15].
Thus, further clarification of the effects of HT on normal
human mammary gland is required [16].
The optimal method for estimation on the effects of HT
on normal breast epithelium is a large-scale clinical study
in a normal human population. However, these studies
take years and need great numbers of healthy volunteers.
On the other hand, studies using cell lines and experimen-
tal animals (e.g. rodents), although helpful, have their
limitations [17] due to lack of epithelial-stromal interac-
tion in cell lines or the biological differences between
human and rodent mammary glands [16]. However, there
are also some studies on macaque's mammary glands,
which have well-documented similarities to the anatomy
of human mammary gland, reproductive physiology and
peripheral steroid hormone metabolism [18-20]. These
studies are of great value, but they are expensive, taking
months or years and need animal sacrifice.
Experimental models have shown the importance of epi-
thelial-stromal interaction for proliferation and differenti-
ation of epithelial cells both in vivo and in vitro [21-25].
The advantage of tissue culture over cell lines lies in the
maintenance of the three-dimensional structure of the tis-
sues and in the maintenance of epithelial-stromal interac-
tions. There is evidence for tissue-specific hormonal
effects to be maintained more properly in tissue culture
when compared to primary culture models [21-25].
The human breast culture provides a useful in vitro model
to monitor the response of the breast tissue to various
HTs. There have been reports of human breast organ cul-
tures in vitro [26-29], but they have been mainly morpho-
logical studies and only a few of them have included data
on regulation and expression of steroid hormone recep-
tors [16]. Normal glandular tissue can be obtained from
three different types of procedure: reductive breast sur-
gery, surgery performed for benign tumours and normal
epithelium surrounding the tumour (peritumoral tissue
or adjacent to tumour tissue). The main source of normal
breast tissue for culturing in vitro is reductive mammo-
plasties, which are mostly performed on women in repro-
ductive age.
The aim of this study has been to evaluate the changes
caused by 17β-estradiol (E2) and medroxyprogesterone
acetate (MPA) on the postmenopausal human mammary
gland in vitro. E2 and MPA are widely used as HT by pre-
and postmenopausal women. Therefore, we used peritu-
moral tissue (non-tumour areas), which wasobtained
from postmenopausal patients in breast tumour opera-
tions.
In this work, culture conditions for freshly isolated
human breast tissues were established and the in vitro
effects of E2 and MPA were studied on breast histology,
differentiation markers, expression of steroid hormone
receptors, proliferation and apoptosis ratios in cultured
breast explants. These results demonstrate that the mor-
phological integrity of human breast explants can be
maintained in organ culture up to 3 weeks.
Methods
Ethics
The study protocol was approved by Joint Ethical Com-
mittee of Turku University and Turku University Central
Hospital. An informed written consent was obtained from
all patients before the surgery.Page 2 of 14
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Human breast tissues were acquired from nine female
patients aged 49–64 years, undergoing breast surgery for
breast tumours (n = 9). The normal tissue that we used
was taken from the border area between normal tissue
and excised tissue. Histologically these tissues pieces con-
tained normal epithelium. Tissue were transported to the
laboratory in cold, phenol-red free DMEM/F12 medium
(GIBCO, England) supplemented with penicillin (100
IU/ml) and streptomycin (100 μg/ml). The cultures were
started within 1–2 h after surgery. The tissues were cut in
DMEM/F12 medium. First, breast tissue was carefully dis-
sected under a stereo microscope to exclude as much of
adipose tissues as possible saving the collagenous connec-
tive tissues, because the ducts and lobules are found
mostly in the tan collagenous stroma. The collagenous
connective tissues were cut with a fine scissors approxi-
mately into 2 × 2 × 2-mm3 pieces.
Organ culture
The culture method of Trowell was used with some mod-
ifications [24-26]. Four to seven pieces of breast explants
were transferred onto lens papers lying on stainless steel
grids in Petri dishes and cultured for different periods (Fig.
1). The explants were kept in a humidified atmosphere
with a mixture of 5% CO2 and 95% air at 37°C in phenol-
red free DMEM/F12 medium (GIBCO, Paisley, UK) sup-
plemented with 10% dextran-charcoal stripped fetal calf
serum, penicillin (100 IU/ml), streptomycin (100 μg/ml),
0.5 ml ITS supplement (Sigma, Steinheim, Germany), 100
nM hydrocortisone (Sigma) and 10 ng/ml EGF (Sigma).
This medium was referred to as basal medium. 10 nM E2
(Sigma), 100 nM MPA (Sigma) or a combination of 10
nM E2 and 100 nM MPA was added to the basal medium.
These concentrations of steroid hormones were used
according to previous study [16]. The solubility of MPA in
ethanol was poor, therefore all steroids were dissolved in
dimethylsulfoxide (DMSO, Sigma), in which many bio-
logically active compounds have a high solubility. Con-
trol tissues were cultured in basal medium, supplemented
with solvent (DMSO). The medium was changed every
second day and fresh batches of steroids were added. Two
to three parallel dishes with samples obtained from each
patient were cultured for every treatment group and every
time point.
The final concentration of DMSO in the culture medium
was 0.03 %. Explants were collected 7, 14 and 21 days
after the beginning of the culture.
Histology
Non-cultured (day 0) and cultured mammary gland tis-
sues were fixed in 4% paraformaldehyde in phosphate-
buffer overnight (o/n) at +4°C, then dehydrated, and
embedded in paraffin according to routine procedures.
Paraffin sections of 5 μm were cut from each piece and
stained with hematoxylin and eosin (H&E) for histologi-
cal examination and from same paraffin blocks, sections
were cut for immunohistostainings.
Immunohistochemistry
For immunohistochemical staining, 5 μm thick paraffin
sections were mounted on Super-Frost Plus (Menzel-
Gläser, Germany) slides. All primary antibodies used in
this study were commercially available mouse primary
anti-human antibodies (Table 1). After dewaxing in
xylene and rehydrating through graded alcohol series fol-
lowed by water, endogenous peroxidase in the sections
was blocked by immersion for 10 min in a solution of 3%
H2O2 and 100% methanol. The slides were treated for
antigen retrieval by boiling in a microwave oven in 0.01
M citrate buffer and 0.5% Tween 20 (pH = 6.0) for 15
min. After washing with PBS (pH 7.4), the sections were
incubated with 2% normal horse serum for 30 min at RT
to block non-specific binding. Then sections were incu-
bated with primary antibodies at different dilutions o/n at
+4°C. PBS was used for all subsequent washes and for
dilution of the antibodies. The slide detected positive for
antigen was used as positive control, and the slide incu-
bated without primary antibody was used as negative con-
trol for each staining batch. After a further wash step,
biotinylated horse anti-mouse secondary antibody
(1:200, Vector, USA) was applied for 2 hours at RT. Visu-
alization was carried out by means of the avidin-biotin
peroxidase complex (ABC, Vector, USA) for 1 hour, fol-
lowed by diaminobenzine tetrahydrochloride (DAB, Vec-
tor, CA) as chromogen in distilled water. Finally, all
sections were counterstained by Mayer's hematoxylin for
14 sec., dehydrated and mounted with Mountex (His-
toLab, Göteborg, Sweden) mounting medium.
Image analysis and histomorphometry
The sections were interpreted under light microscopy in
high-power fields. An Olympus BX-60 (Olympus Optical
Co. GmbH Hamburg, Germany) microscope connected
The modified in vitro culture method used in the present studyFigure 1
The modified in vitro culture method used in the present 
study.Page 3 of 14
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417) System GmbH was used for the image analysis.
Histomorphometric evaluation was performed to esti-
mate the changes of epithelial morphology (acinar and
ductal wall thickness) during different hormonal treat-
ments. The same sections assessed for histological exami-
nation (H&E-stained slides) were analyzed for
histomorphometry. All morphometric measurements
were done on H&E-stained slides, using OsteoMeasure™
system (OsteoMetrics, Inc., Atlanta, USA). Morphometric
measurements of ducts and acini were performed with the
help of digitizing interactive video overlay drawing system
run by this morphometry program. The acinar and ductal
profiles were measured by outlining their images on the
monitor screen with the computer mouse. In each sample,
eight microscopic fields (four for ducts and four for acini)
were randomly selected and examined at ×200 magnifica-
tion. The breast structures were quantified by digital trac-
ing, and the wall thickness (μm) of ducts and acini were
measured with exclusion of the lumens (Fig. 3A,B).
Fragment end labelling of DNA (FragEL™)
A DNA fragmentation assay (Klenow FragEL™ DNA Frag-
mentation Detection Kit, Calbiochem, Germany) was
used to detect apoptotic cells in paraffin-embedded tissue
sections. All procedures were carried out according to
manufacturer's instructions. Briefly, after deparaffination
and rehydration of tissue sections in graded alcohol, the
sections were subjected to proteinase K treatment for 20
min at RT to enhance the sensitivity of the DNA end label-
ling. The endogenous peroxidase activity was blocked by
incubating the slides in 0.3% hydrogen peroxide in water
for 10 min at RT. Biotin-labelled deoxynucleotides were
catalytically added to 3'-OH groups at the ends of DNA
fragments by Klenow enzyme (DNA polymerase I) during
a 90-min incubation at 37°C. Nucleotides incorporated
into fragmented DNA were detected after incubation with
streptavidin-horseradish peroxidase conjugate (30 min at
RT) followed by visualization with 3,3-diaminobenzidine
(4 min. at RT) as a chromogen and methyl green as a
counterstain. Negative controls were obtained by omit-
ting Klenow enzyme from the reaction buffer. Cells were
counted as apoptotic only if they were FragEL-positive
(brown) and showed characteristic morphological fea-
tures typical of apoptosis (cells containing pyknotic nuclei
and apoptotic bodies). FragEL-index or apoptosis ratio
was defined as the number of FragEL-positive cells
(brown) per 1000 epithelial cells counted (brown+green)
in sections representing each explant in every culture.
Quantification of immunohistochemical stainings
All immunostainings were quantified in specific breast
structures by counting the proportion of immunostained
cells in different compartments (inter- and intralobular
ducts or terminal ductules and lobules) of breast tissue.
Only normal areas of breast tissues were evaluated. Areas
with fibrocystic changes, hyperplasia, microcalcifications,
and metaplasia were excluded from the analysis. The
expression of all markers was evaluated only in glandular
epithelium – luminal epithelial cells (LEC) and myoepi-
thelial cells (ME). The immunostainings were evaluated
according staining percentage of the positive cells (Ki67,
PCNA, ER, PR) and staining intensity in nucleus (Ki67,
PCNA, ER, PR) or cytoplasm (CK8&18, K-14, SMA).
The percentage of positive cells
Different cut off percentages of cells with positive immu-
nostaining have been chosen for various markers. For Ki-
67 staining, the explants with over 1% of the nuclei being
stained were considered positive and for PCNA staining
the explants with over 5%. The fraction of immunoposi-
tive nuclei relative to all nuclei of cells (staining fre-
quency) determined for 1000 epithelial cell nuclei for
each sample to obtain a reliable estimate of the PCNA or
Ki-67 proliferation index [30,31].
A specimen was considered positive for ER or PR if stain-
ing of ≥10% of nuclei of epithelial cells was seen [32]. For
quantification of ER or PR immunostainings an eyepiece
grid of 10 × 10 squares at ×200 magnification was used
and the positive epithelial cells crossing 100 consecutive
squares were counted [33]. Positive cells were counted in
extra lobular ducts and terminal-lobular units (TDLU),
consisting of acini and small ducts. Numbers of squares,
which contained one or more positive cells, were
Table 1: The monoclonal primary mouse antibodies used in this study.
Primary antibody Company Antibody dilution Staining pattern
Actin, Smooth Muscle Ab-1 NeoMarkers, Fremont, USA 1:400 Cytoplasmic
anti-Cytokeratin 8&18 Zymed® Laboratories Inc, South San Francisco, CA 1:250 Cytoplasmic
anti-Human Estrogen Receptor – alpha DakoCytomation, Glostrup, Denmark 1:2000 Nuclear
Anti-PCNA Zymed® Laboratories Inc, South San Francisco, CA 1:200 Nuclear
Estrogen Receptor – beta Novocastra, Newcastle Upon Tyne, UK 1:800 Nuclear
Keratin 14 Ab-1 NeoMarkers, Fremont, USA 1:400 Cytoplasmic
Ki67 Antigen Novocastra, Newcastle Upon Tyne, UK 1:100 Nuclear
Progesterone Receptor (A/B Forms) Novocastra, Newcastle Upon Tyne, UK 1:100 NuclearPage 4 of 14
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squares.
Immunostaining intensity
The mean staining intensity was estimated and expressed
as weak (yellow or light-brown cytoplasmic or nuclear
staining), moderate (dark-yellow or medium-brown stain-
ing, or a mixture of light and dark staining) or strong
(dark-brown staining in nucleus or cytoplasm).
Statistical analysis
Statistical analysis was performed using SAS System soft-
ware version 9.1.3 (General Mixed Model Analysis of Var-
iance). This analysis estimates the correlation of variables
(acinus and duct wall thickness, Ki67, PCNA, FragEL, ERα,
ERβ, PR) with time (day 7, 14, 21), treatment groups
(control, E2, MPA, E2+MPA) and interaction between day
of culture and treatment. The variables obtained from cul-
tured explants were pooled and used for calculation of the
means and standard deviations. The first analysis was
done separately for each day (3 different days) with treat-
ment (4 different treatments) as the fixed factor and sub-
jects (individual patients) as random. In the second
analysis treatment and day and their interaction were
fixed factors and subjects were random. Pairwise compar-
isons between different treatments were adjusted using
the Tukey-Kramer method. Assumptions were checked
using analysis of residuals. All the results are expressed as
means ± SD. P-values less than 0.05 were considered to be
significant.
Results
Histological examination of cultured human breast tissue
Histological examination showed that inter- and intralob-
ular ducts (ducts), terminal ductules and lobules (termi-
nal duct-lobular unit, TDLU) and stroma had retained
their morphological structures throughout the culture
period of 21 days. Histological analysis of breast tissues
revealed differences in the appearance of the epithelium
between the different treatment groups (Fig. 2A–J). The
lobules (acini) of mammary tissue before culture (D 0)
and after 21-days in basal medium (D 21) were small,
compact and similar in appearance (Fig. 2A,B). In con-
trast, in the E2, MPA and E2+MPA groups, lobules were
larger and less compact, the epithelium height was
increased. In E2-treated explants, the epithelial cells often
appeared hyperplastic and in some cases, there was a loss
of distinction between duct lining cells and myoepithelial
cells. The size of the cells and the number of cell layers was
increased. There was also a tendency of epithelium to
overgrow and obliterate the basement membrane (Fig.
2E,F). In the explants cultured with MPA the acini were
large and the lumina were filled with secretion (Fig.
2G,H). In the explants cultured with E2+MPA the number
of epithelial cell layers in the ducts was increased (Fig.
2I,J).
Histomorphometrical analysis of cultured explants
The thickness of acinar and ductal wall was increased by
treatment with E2, MPA and E2+MPA. All measured values
(the acinar and ductal wall thickness) were greatest for
explants treated with E2 for 7, 14 and 21 days, but the dif-
ferences between the treatment groups (E2, MPA and
E2+MPA) vs. control groups at day 7 did not reach statisti-
Histology of human breast before and after organ cultureFigure 2
Histology of human breast before and after organ culture. The histology analysis of explants revealed differences in the 
appearance of epithelium before and after organ culture. The acini (A) and ducts (B) before organ culture (D 0) and after 21 
days (D 21) in basal medium (C-D); (E-F) the epithelium in explants cultured with E2; (G-H) the epithelium in explants cul-
tured in the presence of MPA; (I-J) the epithelium in explants cultured with E2+MPA. (H&E staining. Scale bar 100 μm).Page 5 of 14
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icant differences in thickness between hormone treatment
groups and control, but statistical significance was not
observed between hormonal treatment groups – E2 vs.
MPA, E2 vs. E2+MPA or MPA vs. E2+MPA. After 21 day of
organ culture, only the difference between E2 and control
was statistically significant. The hormone effects on acinar
wall thickness were comparable to those on the ductal
thickness (Fig. 3).
Expression of differentiation markers
Next we investigated how culturing conditions and the
presence of different steroid hormones affect the struc-
tural components of the human mammary gland. For this
purpose we chose markers for luminal and myoepithelial
cells. Immunostaining for Cytokeratin 8&18 (CK8&18),
Keratin-14 (K-14) and Smooth Muscle Actin (SMA) were
used to investigate the effect of various hormones on the
structure and differentiation of cultured human breast
Histomorphometrical method used to determine acinar and ductal wall thickness in cultured human breast explantsFigure 3
Histomorphometrical method used to determine acinar and ductal wall thickness in cultured human breast 
explants. The areas outlined in black represent the measured sector of acini (A) and ducts (B). Columns represent the mean 
counts ± SD. Asterisks indicate the statistical significance of differences between control and treatment groups (*, p < 0.05; **, 
p < 0.01) and NS, not significant. The differences between treatment groups E2 vs. E2+MPA, E2 vs. MPA and MPA vs. E2+MPA did 
not reach statistical significance at any day of organ culture. (H&E staining. Scale bar 100 μm).Page 6 of 14
(page number not for citation purposes)
BMC Cancer 2006, 6:246 http://www.biomedcentral.com/1471-2407/6/246explants (Fig. 4A–H). CK 8&18 is a marker for luminal
epithelial cells (LEC) and SMA for myoepithelial cells
(ME). K-14 is a ME marker in normal tissue, whereas in
transformed tissues it is regarded as a "proliferation" anti-
gen (Fig. 4A,B).
Expression of CK8&18 and K-14 in explants were detected
on days 0 and 21 of the experiment. Compared with non-
cultured samples from the same patient, the immunos-
taining for CK8&18 was slightly declined after 21 days in
the control, MPA and E2+MPA groups. A moderate inten-
sity of CK8&18 immunostaining was observed in the E2
group (Fig. 4F). The immunostaining of Keratin-14 in E2
group after 21 days of culture showed that the epithelial
cells positive for this marker were scattered throughout
the acini (Fig. 4D) and in control group only ME were
stained.
Immunostaining of SMA was found in the myoepithe-
lium and stroma as well. The staining decreased markedly
from day 0 to day 21 in the E2 group compared to control
(Fig. 4H). In other treatment groups, the staining
decreased slightly compared to control, but less than in E2
group.
Assessment of Ki-67 and PCNA expression in cultured 
breast tissues
Ki-67 and PCNA were studied immunohistochemically to
investigate the effects of different culture conditions on
cell proliferation. Expression of both proliferation pro-
teins was detected on days 7, 14 and 21 of culture. The
percentage of epithelial cells detected with the anti-PCNA
antibody was significantly greater than that detected with
the Ki-67 antibody (Fig. 5A–I).
Immunostaining intensity
Immunostaining of Ki-67 was seen mainly in epithelial
cells, but PCNA staining was detected in both epithelial
and stromal cells. The staining intensities of PCNA and Ki-
67 were estimated to be strong after 7 days of culture with
E2 and moderate in the MPA and E2+MPA groups. In basal
culture medium, intensity was estimated as moderate at 7
days and weak at day 21. In the E2 and E2+MPA groups
from day 7 onwards, there were more PCNA and Ki67
positive cells in ductal epithelium compared to acinar epi-
thelium. In control groups, TDLU and ducts stained simi-
larly for Ki67 and PCNA at days 7, 14 and 21 days of organ
cultures.
Proliferation indices
Proliferation indices (PI) were calculated on the basis of
immunostaining of epithelial cells for Ki-67 and PCNA.
The percentages of Ki-67 and PCNA positive cells per
Immunohistochemistry of differentiation markers in human breast explantsFigure 4
Immunohistochemistry of differentiation markers in human breast explants. (A-B) Immunohistochemistry of K-14 
before organ culture. Note that the myoepithelial cells of the normal tissue have heavy brown cytoplasmic stain (A). In tumoral 
tissue the K-14 positive cells are scattered throughout the acinus (B), thus, it does not label anymore myoepithelial cells. (C, E, 
G) – Expression of K-14, CK8&18 and SMA respectively in non-cultured human breast tissues. (D, F, H) – Expression of K-14, 
CK8&18 and SMA in breast explants cultured with 10 nM E2 for 21 days. (Scale bar, 100 μm).Page 7 of 14
(page number not for citation purposes)
BMC Cancer 2006, 6:246 http://www.biomedcentral.com/1471-2407/6/246
Page 8 of 14
(page number not for citation purposes)
Proliferation and apoptosis in human breast explantsFigure 5
Proliferation and apoptosis in human breast explants. Proliferation in human breast explants (n = 9) at various time 
points and treatment groups was determined by Ki-67 and PCNA, and apoptosis by FragEL™. Comparison of expression of 
Ki-67 positive cells in explants cultured for 7 days (A-acini, B-duct) with explants cultured for 14 days (C-acini, D-duct) in vitro 
with E2. Note that cell proliferation was increased after 14 days (p < 0.001). Examples of expression of PCNA in E2 treatment 
groups after 7 (F-acini, G-duct) and 14 days of culture (H-acini, I-duct). Note that intensity of PCNA staining diminished after 
14 days when compared with staining intensity after 7 days of culture. Cell apoptosis in cultured explants after 21 days: (K)-
control group; (L)-10 nM E2 group; (M)-100 nM MPA; (N)-10 nM E2 and 100 nM MPA group. The number of apoptotic cells 
decreased in all hormone treatment groups compared with control at 7, 14 and 21 days in vitro. Proliferation (Ki67, a, and 
PCNA, b) and apoptosis ratios (FragEL™, c). Proliferation and apoptosis indices were counted per 1000 epithelial cells at days 
7, 14 and 21 of organ culture with different hormonal treatments. Columns represent the mean counts ± SD. Asterisks show 
the statistical significance of differences between control and hormonal treatment groups (*, p < 0.05}; **, p < 0.01}; ***, p < 
0.001), NS not significant.
BMC Cancer 2006, 6:246 http://www.biomedcentral.com/1471-2407/6/2461000 common epithelial cells in explants were expressed
as PI for Ki-67 and PCNA. PI increased during organ cul-
ture in the presence of E2, MPA and E2+MPA.
PI for Ki-67 in the explants cultured in the presence of E2
was significantly greater when compared to control group
at days 7 (p < 0.01) and 14 (p < 0.001) of the organ cul-
ture, but after 21 days of culture, the difference was not
statistically significant. At 7 and 14 days other treatment
groups as MPA and E2+MPA showed also significant dif-
ferences (p < 0.05) vs. control group (Fig. 5a). Results with
PCNA were comparable to the Ki-67 results, except that
the difference between the E2 vs. control groups reached
statistical significance (p < 0.05) after 21 days (Fig. 5b).
Although the mean of PI values for the E2 group were
highest after 7 and 14 days of culture, there were no statis-
tically differences among the treatment groups E2 vs. MPA,
E2 vs. E2+MPA or MPA vs. E2+MPA.
Estimation of the rate of apoptosis
Apoptosis was observed mainly in epithelial cells. Steroid
hormone addition to the culture medium affected apop-
tosis ratio in vitro. There were less apoptotic cells in all
treatment groups (E2, MPA and E2+MPA) when compared
to the control group (Fig. 5K–N).
The lowest apoptosis indices were found in the E2 treat-
ment groups after 7 (p < 0.01), 14 (p < 0.01) and 21 (NS)
days of culture compared to the control group. The differ-
ence between E2, MPA and E2+MPA vs. control groups did
not any more reach a statistical significance after 21 days
(Fig. 5c).
Expression of ERα, ERβ and PR
Effects of different hormone treatments on expression of
ERα, ERβ and PR were studied next. Non-cultured tissue
samples were first immunostained for ERα, ERβ and PR.
Only explants prepared from positive specimens were
stained after culture period (Fig. 6A–O). Expression of
ERα and ERβ was found in 67% and 100% of non-cul-
tured samples, respectively. On average, ERα and ERβ
labelling slightly decreased after 21 days of organ culture,
compared to non-cultured samples or the control group at
day 21 of culture. In general, all used hormonal treat-
ments seemed to be associated with down-regulated
expression of ERα (Fig. 6a) and ERβ (Fig. 6b). Expression
of PR was found in 56% of the non-cultured samples. A
strong positive immunostaining was observed for PR in
explants cultured with 10 nM E2 substitution compared
with MPA and E2+MPA groups. In the MPA and E2+MPA
treatment groups, no PR or very faint staining for PR was
detected (Fig. 6N,O).
Discussion
Our results demonstrate that human mammary gland
explants can be maintained viable in an organ culture sys-
tem for 3 weeks without a major loss of tissue architecture.
The results also show that addition of E2, MPA or combi-
nation of E2 and MPA to culture medium increased the
rate of epithelial proliferation and decreased the apoptotic
ratio. In addition, expression of estrogen and progester-
one receptors was down regulated during these hormonal
treatments in vitro.
Human breast tissue explants cultured by this method
retained their morphological integrity. The presence of all
tissue components in this model allows the investigation
of the interactions between epithelium and stroma which
have been demonstrated to be important for maintenance
of the differentiated state of breast epithelium [22-25].
The morphology of explants cultured in basal culture
medium without additions showed viable tissue with low
acinar and ductal epithelium. Cultures in the presence of
E2 and MPA or combination of both of them caused stim-
ulatory effects on acinar and ductal epithelium. The
number of epithelial cells increased, epithelium was lay-
ered and its height was elevated. Expression of differenti-
ation markers was also affected by addition of various
steroid hormones in the culture medium. The explants
treated with E2 for 21 days showed decreased intensity
staining for SMA, CK8&18 and K-14 positive epithelial
cells scattered throughout the acini. The altered pattern of
expression of differentiation markers along with the over-
all hyperplastic and slightly disorganised epithelial mor-
phology suggests E2 decreased the level of differentiation
of glandular epithelium in vitro.
Histomorphometry was performed on cultured explants
to determine whether hormonal treatment affected epi-
thelial parameters. We measured two morphometrical
variables – acinar and ductal wall thicknesses. Histomor-
phometrical analysis revealed that the relative areas of
glandular tissue components (acini and duct) increased
among treated groups. Corresponding histomorphomet-
rical analysis was done on human and macaques mam-
mary gland treated in vivo with conjugated equine
estrogen (CEE) with or without MPA [24,25]. These stud-
ies demonstrated that glandular tissue areas were greatest
in CEE+MPA group. The results are contrary to ours,
because we found that the highest epithelial thickness was
in the explants treated with E2 only.
We also found that E2, MPA and their combination
increased epithelial proliferation. In addition, Ki67 and
PCNA proliferation indices for E2 group were constantly
higher than for MPA or E2+MPA groups, although the dif-
ferences between the treatment groups did not reach a sta-
tistical significance.Page 9 of 14
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recent years to identify proteins that are responsible for
regulation of cell proliferation. Anti-PCNA and Ki-67 anti-
bodies detect two different proteins present in cycling
cells and have both been widely used to measure levels of
proliferative activity in human tissues [34].
In vivo studies have reported conflicting results regarding
proliferative activity in breast epithelial cells based on
Ki67 and PCNA immunostainings. However, others and
our study have demonstrated that E2 stimulated breast
epithelial cell proliferation more pronounced than MPA
or E2+MPA. Foidart et al. showed in a prospective study
(where postmenopausal women received topical treat-
ments with gels containing placebo, E2, progesterone (P)
or E2 + P applied directly to their breast for two weeks)
that E2-alone increased the PI (PCNA) of breast epithe-
lium 100-fold, P-alone 15-fold and E2+P combination
gave an 13-fold increase [35]. Our in vitro results are in
accordance with these observations. We observed prolifer-
ative response to hormonal treatment, especially with E2,
similar as it was shown by Anderson et al. [36,37]. In their
in vivo study pieces of human mammary gland were trans-
planted onto immune-compromised mice, which subse-
quently were treated with E2 and progesterone at the
adequate doses of follicular or luteal phase of woman's
menstrual cycle. They found that luteal phase concentra-
tion of E2 stimulate epithelial cell proliferation in normal
Expression of steroid receptors in human breast explantsFigure 6
Expression of steroid receptors in human breast explants. Immunohistostainings of the steroid hormone receptors – 
ERα (A-E), ERβ (F-J) and PR (K-O). The effects of various hormonal treatments on the immunohistochemical expression of 
steroid hormone receptors – ERα (a), ERβ (b), PR (c). Columns represent the mean counts of positively stained cells ± SD. 
Asterisks indicate the statistical significance of differences between control and hormonal treatment groups (*, p < 0.05; **, p < 
0.01; ***, p < 0.001), NS not significant. (Scale bar, 100 μm).Page 10 of 14
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ment alone had no effect compared to no treatment.
Other studies reported that oral E2-alone HT was associ-
ated with a smaller effect than E2+MPA on cell prolifera-
tion and epithelial density [20,31]. Some of the
controversies between our results in vitro and in vivo find-
ings can possibly be explained by differences in routes of
administration and dosages of steroid hormone used. The
route of administration influences the pharmacology of
exogenous sex hormones. After oral administration, sex
hormones are metabolised in liver and the intestinal tract
to less active metabolites. When topically administered,
peripheral aromatisation in fat and breast tissues may
occur. Consequently, the concentrations in blood serum
and target tissues may be different. When hormones con-
taining gel was applied directly on breast skin, a high tis-
sue concentration of E2 and the highest PI were obtained
[35].
In vitro sex hormones are directly added to the culture
medium and they affect the cells and tissues directly with-
out any systemic effects. However, the effective concentra-
tions may differ from physiological ones. In comparison
with range of E2 in blood serum (around 2 × 10-10 M) we
have used a higher concentration, because the short-term
presence of high concentrations and the long-term pres-
ence of low concentrations of estradiol cause a similar
expression of estrogen-dependent products during a time
interval of 12–48 h [38]. The clinically relevant blood
concentration for MPA used for HT is 4 × 10-9 M to 4 × 10-
8 M, but in a previous in vitro study lower concentrations
did not produce any response [15,16].
It should be noticed that human breast is one of the few
organs of the body that is not fully developed at birth. The
full differentiation of mammary gland is reached only
during pregnancy and lactation, by influence of specific
hormones [39]. There are differences in histological struc-
ture of TDLU at various ages of woman's lifespan, which
represent different stages of mammary gland develop-
ment [39,40]. Four lobule types have been known so far.
The lobule type 1 is the most undifferentiated structure,
which is mainly found in postmenopausal breast. Lobule
type 1 is associated with the highest level of cell prolifera-
tion, decreasing progressively in lobule type 2, 3 and 4
[39,41]. We cultured postmenopausal women's breast tis-
sues containing mostly undifferentiated epithelial cells,
which have a high capacity to proliferate by influence of
various endogenous and exogenous stimuli such as ster-
oid hormones. We found an intensive proliferative
response and, consequently, an increased epithelial den-
sity in hormonal treatment groups.
It is known that hormone-induced cellular proliferation
can alter susceptibility to carcinogens or mutogens [42].
Uncontrolled cell proliferation is considered a hallmark
of tumorigenesis. Our results showed that besides prolif-
eration also apoptosis ratios were dependent on hormo-
nal treatments. Especially treatment with E2 decreased
apoptosis ratio in the epithelial cells as has been shown in
breast cancer cells [43].
The effects of E2 and P on the mammary gland are medi-
ated by their nuclear receptors – ER and PR [44]. Two
forms of ER, namely ERα and ERβ, encoded by different
genes, are known [45]. Progesterone receptor also has two
isoforms – PRA and PRB, which are coded for a single
gene. ER and the two isoforms of PR have different distri-
bution in human breast [46]. ERα is expressed at a low
level only in luminal epithelial cells of resting mammary
gland (~ 10–20%). During lactation 80% of the luminal
cells express ERα [46]. ERβ is expressed not only in lumi-
nal epithelial, but also in myoepithelial and stromal cells.
ERβ is dominant in the resting mammary gland and its
levels are high in normal breast tissue (~ 70%) [47]. PR
has been shown to be present, like ERα, only in luminal
epithelial cells (15–30%) [48]. Using the dual-label
immunofluorescent techniques, an almost complete co-
expression between ERα and PR (96% of the cells express-
ing PR also contain ERα) has been reported [48].
In normal breast tissue only differentiated cells are con-
sidered to express ERα or PR and they do not proliferate
[44]. Undifferentiated cells (the stem cell/early transit cell
populations) are capable to proliferate [49]. Almost every
proliferating cell is adjacent to one expressing ERα and PR
[49]. Therefore it is possible that ERα and PR-positive cells
control the proliferation activity of undifferentiated cells
via juxtacrine and/or paracrine signals depending on the
prevailing estrogenic environment [50].
We found that the relative numbers of ERα, ERβ and PR
positive cells in the presence of steroid hormones were
decreased after 21 days of culture, especially ratios of PR
positive cells in MPA and E2+MPA groups. Generally, ster-
oid hormones regulate the expression of their own recep-
tors. During the menstrual cycle, as E2 levels increased,
ERα is down-regulated, whearas ERβ is up-regulated [51].
These results are consistent with our finding that in E2
treated explants, ERα expression in epithelial cells is
decreased. To the contrary previous study, we found that
expression of ERβ decreased in the presence of steroid
hormones. Both in vitro and in vivo experiments have indi-
cated that ER beta exerts an antiproliferative effect on
human breast cells [52]. ERβ expression is relatively high
in the normal breast, which is inversely correlated with
cellular proliferation. There are some data showing that
ERβ expression is downregulated in lesions such as atypi-Page 11 of 14
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in normal epithelium. Although reduced, invasive breast
carcinomas show high levels of ERα and ERβ with approx-
imately two thirds of the tumors staining positive by
immunohistochemistry [53]. These elevated expressions
of ERs are associated with dysregulation of proliferation
(increased numbers of proliferating cells) [6].
Our results showed a proliferative response to exogenous
E2 and progestin treatment, which was accompanied by a
decrease in the number of ERβ cells. Steroid hormones
suppressed the ratio of ER and PR positive cells, which are
though to be the most differentiated ones that control the
proliferative activity of less undifferentiated epithelial
cells in breast tissue.
Many studies have shown that progesterone down-regu-
lates its own receptor and antagonizes the estrogen action
by inhibiting the synthesis of ERs [54,55]. Our results
show an unexpected E2 reduction of PR in epithelial cells
of breast explants. This result contradicts the original
report made by Anderson et al. that E2 upregulated PR
expression in human mammary gland xenografted into
athymic nude mice [36,37].
There are also previous reports on a complete dissociation
between the level of steroid receptor (ERα and PR) expres-
sion and proliferation rate in normal human mammary
epithelium [6]. Our results showed that postmenopausal
breast tissue in vitro responded to exogenous stimuli (hor-
monal treatment) with intensive proliferative response
associated with a decreased relative number of ERα, ERβ,
PR positive cells. We observed the inverse relationship
between steroid receptor expression and proliferation in
our in vitro model (proliferation ratios increased and
simultaneously the number of ER, PR positive cells
decreased). On the other hand, a loss of inverse relation-
ship between steroid receptors and proliferation rate was
reported to occur at the earliest stages of breast tumorigen-
esis (increasing the number of proliferating cells with
increase of expression of ER, PR) [50]. Dysregulation of
the relationship between steroid receptor expression and
proliferative activity in our cultures may also be associated
with the fact that the tissue samples were obtained from
breast tumour patients even if the histology of explants
was normal. Even so they provide a valuable model for
studies on the effects of E2 and progestin treatment on epi-
thelium of postmenopausal mammary gland and the
mechanisms of dissociation of hormone regulation of
receptor levels and proliferation.
Taken together, it seems that in vitro the postmenopausal
breast tissues possess mostly undifferentiated epithelial
cells [39], which respond to exogenous stimulus pro-
duced E2 but also progestin and their combination treat-
ment with a proliferative response and decreased number
of ER and PR positive cells.
Conclusion
The present study indicates that organ culture provides a
vitro model in which architecture of human mammary
gland can be maintained. The results obtained by using
organ cultures demonstrated direct effects of E2 and MPA
on the proliferation and differentiation on human breast
tissue without the interference with the systemic effects
found in vivo.
It is well-known that estrogens and/or progestogens can
influence proliferation either directly by regulating the
cell cycle [56] or indirectly by regulating production of
stimulating or inhibiting stromal or epithelial growth fac-
tors [15,57]. Thus, organ cultures in many aspects provide
a more appropriate model for estimation of the prolifera-
tive effects of various factors and compounds than cell
cultures. The advantage of this method is that the proper
connection between stromal and epithelial cells is main-
tained.
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